 |
市場調査レポート
商品コード
1455118
標的化リポソームドラッグデリバリーの世界市場規模、シェア、成長分析、リポソームタイプ別、用途別、標的化薬剤タイプ別-産業予測、2024～2031年Global Targeted Liposomes Drug Delivery Market Size, Share, Growth Analysis, By Type of Liposomes, By Application, By Targeted Drug Type - Industry Forecast 2024-2031 |
||||||
| 標的化リポソームドラッグデリバリーの世界市場規模、シェア、成長分析、リポソームタイプ別、用途別、標的化薬剤タイプ別-産業予測、2024～2031年 |
|
出版日: 2024年03月18日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
標的化リポソームドラッグデリバリーの世界市場規模は2022年に14億8,000万米ドルと評価され、2023年の15億5,000万米ドルから2031年には22億米ドルに成長し、予測期間（2024～2031年）のCAGRは4.5%で成長する展望です。
世界の標的化リポソームドラッグデリバリー市場は、ドラッグデリバリー技術の進歩によって大きな成長を遂げています。標的化リポソームは、正確かつ制御された薬剤放出を提供し、副作用を軽減し、治療効果を高めます。慢性疾患の有病率の上昇と個別化医療に対する需要の増加は、市場拡大を促進する主要要因です。さらに、継続的な研究開発、戦略的パートナーシップ、医療への投資の高まりが、市場の成長をさらに後押ししています。北米と欧州は強固な医療インフラの恩恵を受け、アジア太平洋は医療の進歩への関心の高まりと患者基盤の拡大により、大きなビジネス機会をもたらしています。注目すべき動向としては、新規製剤の出現や標的化療法の探求などが挙げられ、標的化リポソームドラッグデリバリー市場のダイナミックで発展的な性質が強調されています。
目次
エグゼクティブサマリー
- 市場概要
- 繁栄と衰退
調査手法
- 情報調達
- セカンダリとプライマリデータソース
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主要投資の分析
- 主要成功要因
- 競合の程度
市場力学と展望
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
標的化リポソームドラッグデリバリーの世界市場：リポソームタイプ別
- 市場概要
- PEG化リポソーム
- カチオン性リポソーム
- アニオン性リポソーム
- 中性リポソーム
標的化リポソームドラッグデリバリーの世界市場：用途別
- 市場概要
- がん治療
- 感染症の治療
- 眼科治療
- 心血管疾患の治療
- その他
標的化リポソームドラッグデリバリーの世界市場：標的化薬剤タイプ別
- 市場概要
- 化学療法薬
- 抗真菌薬
- 抗生物質
- 免疫調節薬
- その他
標的化リポソームドラッグデリバリーの世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
- ラテンアメリカ
- ブラジル
- その他のラテンアメリカ地域
- 中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主要市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Alnylam Pharmaceuticals
- Acuity Pharmaceuticals, Inc.
- Jubilant Therapeutics
- Verifor Pharmaceuticals
- BIND Therapeutics
- Paladin Labs
- Lipo Therapeutics
- Pharming Group N.V.
- Johnson & Johnson Services, Inc.
- Gilead Sciences, Inc.
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Janssen Pharmaceuticals, Inc.
- CELSION Corporation
- Abbott
- Ipsen Pharma
- Spectrum Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Roche Holding AG
Global Targeted Liposomes Drug Delivery Market size was valued at USD 1.48 billion in 2022 and is poised to grow from USD 1.55 billion in 2023 to USD 2.20 billion by 2031, growing at a CAGR of 4.5% during the forecast period (2024-2031).
The global Targeted Liposomes Drug Delivery Market is witnessing substantial growth driven by advancements in drug delivery technologies. Targeted liposomes offer precise and controlled drug release, diminishing side effects and enhancing therapeutic effectiveness. The rising prevalence of chronic diseases and the increasing demand for personalized medicine are key factors driving market expansion. Moreover, ongoing research and development efforts, strategic partnerships, and heightened investment in healthcare further propel market growth. Leading in market share, North America and Europe benefit from robust healthcare infrastructure, while the Asia-Pacific region presents lucrative opportunities fueled by a growing focus on healthcare advancements and an expanding patient base. Notable trends include the emergence of novel formulations and the exploration of targeted therapies, underscoring the dynamic and evolving nature of the Targeted Liposomes Drug Delivery Market.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Targeted Liposomes Drug Delivery Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Targeted Liposomes Drug Delivery Market Segmental Analysis
The global Targeted Liposomes Drug Delivery market is segmented into four major segments i.e. by By Type of Liposomes, Application, Targeted Drug Type, and region. Based on Type, it is divided into PEGylated Liposomes, Cationic Liposomes, Anionic Liposomes, Neutral Liposomes. Based on Application, it is bifurcated as Cancer Therapy, Infectious Disease Treatment, Ophthalmological Treatment, Cardiovascular Disease Treatment, Other Therapeutic Areas. Based on Targeted Drug Type it is segregated into, Chemotherapy Drugs, Antifungal Drugs, Antibiotic Drugs, Immunomodulatory Drugs, Other Drug Types. Based on region, the market is segmented into United States, Canada, and Mexico.
Drivers of the Global Targeted Liposomes Drug Delivery Market
The increasing need for customized and precise pharmaceuticals highlights the significant role of focused liposomes as essential drug delivery agents. These specialized carriers enable precise and controlled release, effectively reducing side effects and enhancing therapeutic effectiveness. With the rising prevalence of chronic conditions, notably cancer, there's a heightened focus on advanced drug delivery methods such as targeted liposomes.
Restraints in the Global Targeted Liposomes Drug Delivery Market
One of the key obstacles in the market revolves around the elevated costs associated with cutting-edge liposomal formulations and technologies, potentially impeding widespread accessibility. Moreover, regulatory intricacies and varying approval processes across different regions compound these challenges, potentially prolonging the introduction of new liposomal products into the market.
Market Trends of the Global Targeted Liposomes Drug Delivery Market
The growing emphasis on personalized medicine is driving the exploration of customized liposomal formulations tailored to individual patient needs. Continuous advancements in liposomal technology, including the creation of intelligent and stimuli-responsive liposomes, underscore the industry's commitment to enhancing drug delivery accuracy, reflecting a concerted effort towards precision medicine.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Targeted Liposomes Drug Delivery Market by Type of Liposomes
- Market Overview
- PEGylated Liposomes
- Cationic Liposomes
- Anionic Liposomes
- and Neutral Liposomes
Global Targeted Liposomes Drug Delivery Market by Application
- Market Overview
- Cancer Therapy
- Infectious Disease Treatment
- Ophthalmological Treatment
- Cardiovascular Disease Treatment
- and Other Therapeutic Areas
Global Targeted Liposomes Drug Delivery Market by Targeted Drug Type
- Market Overview
- Chemotherapy Drugs
- Antifungal Drugs
- Antibiotic Drugs
- Immunomodulatory Drugs
- and Other Drug Types
Global Targeted Liposomes Drug Delivery Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Alnylam Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Acuity Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Jubilant Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Verifor Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BIND Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Paladin Labs
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lipo Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pharming Group N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Services, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Janssen Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CELSION Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ipsen Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Spectrum Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
